PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Valenzuela, Fernando
TI  - Health-Related QOL Improved with Tofacitinib in Patients with Psoriasis
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 9--10
VI  - 14
IP  - 37
4099  - http://mdc.sagepub.com/content/14/37/9.short
4100  - http://mdc.sagepub.com/content/14/37/9.full
AB  - Moderate to severe plaque psoriasis has both physical and psychological effects, leading to major impairment of health-related quality of life. Tofacitinib, an oral Janus kinase inhibitor, was found to be effective in A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety Comparing CP- 690,550 and Etanercept in Subjects With Moderate to Severe Chronic Plaque Psoriasis [NCT01241591]. The objective of this analysis of the tofacitinib phase 3 trial was to assess the effects of tofacitinib (5 and 10 mg, BID) versus etanercept or placebo on patient-reported outcomes.